source
- FDA flags safety concern after four deaths in schizophrenia drug trialThe U.S. Food and Drug Administration issued a warning after four participants died while receiving an experimental treatment for schizophrenia in a clinical study. The agency described the observ…
- Viatris to acquire Pacira BioSciences for $1.65 billion to expand non‑opioid pain portfolioViatris announced a $1.65 billion acquisition of Pacira BioSciences, aiming to broaden its non‑opioid pain‑relief offerings. The deal includes Pacira's marketed products Exparel and Zilretta, which…